Academ-AI

Using PCSK9 inhibition as a therapeutic approach for COVID-19 presents several challenges and potential limitations. As of my last knowledge update in September 2023, clinical data supporting its use were limited.¹

Eight months after the original publication of the article, an erratum was published, acknowledging that “the authors omitted to declare their use of AI tools”.² According to the authors, the tools used were Grammarly and QuillBot.

gantt
  dateFormat YYYY-MM-DD
  axisFormat %b %Y
  todayMarker off
  
  Article published : milestone,2024-01-03,2024-01-03
  AcAI contacts journal : milestone,2024-03-19,2024-03-19
  Editor-in-Chief response—will investigate : milestone,2024-03-20,2024-03-20
  Update—authors confirm use of AI tools, erratum to be published : milestone,2024-03-21,2024-03-21
  AcAI request for update : milestone,2024-04-30,2024-04-30
Journal response—erratum being prepared for next available issue : milestone,2024-04-30
  AcAI request for update : milestone,2024-08-12
Journal response—erratum being prepared for next available issue : milestone,2024-08-13
Erratum published : milestone,2024-09-04

Figure 1: Timeline of correspondence between Academ-AI and the journal.

References

¹Arsh H, Manoj Kumar FNU, Simran FNU, et al. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review. Annals of Medicine and Surgery. 2024;86(2):899-908. doi:10.1097/MS9.0000000000001601

²Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review: Erratum. Annals of Medicine and Surgery. 2024;86(9):5659. doi:10.1097/MS9.0000000000002497